Maryam Moossavi

Maryam Moossavi

Auto-generated profile, based on publicly available information

Maryam Moossavi

Department of Molecular Medicine, Birjand University of Medical Sciences, Birjand, Iran

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2022 in Archives of Medical Science
Verified
Journal Article
Open access
SCSajjad Chamani
Sajjad Chamani
OKomid kooshkaki
omid kooshkaki
MMMaryam Moossavi
Maryam Moossavi
MRMandana Rastegar
Mandana Rastegar
SSSara Saffar Soflaei
Sara Saffar Soflaei
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Statins are inhibitors of β-hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR). They are used in patients with cardiovascular risk and/or suffering with cardiovascular disease. In addition to their efficient lipid-lowering effects, statins exhibit independent so called pleiotropic effects potentially affecting several immune response properties including immune cell activation, migration, cytokine generation, immune metabolism, and survival. Statins also regulate innate and acquired immunity. The focus of this review is to highlight the role of statins in modulating the function and differentiation of various blood cells. Given the proposed wider application of these medicines and their potentially important advantages in treatment of inflammatory and autoimmune disorders, more studies are needed with special focus on the molecular targets of statins included in regulating the immune response.

1 May 2015 in DNA and Cell Biology
Verified
Journal Article
Closed access
DJDanial Jahantigh
Danial Jahantigh
SSSaeedeh Salimi
Saeedeh Salimi
MMMahdieh Mousavi
Mahdieh Mousavi
MMMaryam Moossavi
Maryam Moossavi
MMMilad Mohammadoo-Khorasani
Milad Mohammadoo-Khorasani
MSMahnaz Sandoughi
Mahnaz Sandoughi
DNA repair is reduced in patients suffering from systemic lupus erythematosus (SLE), and it can induce the production of autoreactive antibodies due to the accumulation of DNA damage and nucleoprotein that produce immunogenic antigens. The accumulations of anti-Ku and DNA-PKcs antibodies, which are involved in nonhomologous DNA end joining pathway, have been detected in SLE patients. The present study was designed to evaluate the association of XRCC5, XRCC6, and XRCC7 polymorphisms with SLE susceptibility. Polymerase chain reaction (PCR) was performed to genotype 163 SLE patients and 180 healthy controls for the XRCC5 variable number of tandem repeat (VNTR) polymorphism. The genotype analysis of XRCC6-61C>G and XRCC7 6721G>T polymorphisms was performed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. There was a significant association between XRCC5 VNTR, XRCC7 6721G>T polymorphisms and risk of SLE development. Notably, the frequency of XRCC5 VNTR 0R allele and genotypes with 2R allele was greatly enhanced in SLE patients with Malar rash (p=0.032 and p=0.024, respectively). Moreover, a higher frequency of genotypes with the XRCC5 VNTR 2R allele was observed in SLE patients with a positive antinuclear antibody (ANA) test (p=0.03). The present study shows an association between the XRCC5 VNTR, XRCC7 6721G>T polymorphisms and SLE. These polymorphisms might be genetic risk factors for SLE susceptibility and some SLE manifestations in the population southeast of Iran.